new-molecular-drivers-in-nsclc-the-role-of-met
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance - Sacco - Translational Lung Cancer Research
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas - Journal of Thoracic Oncology
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
CytoCell C-MET (MET) Amplification FISH Probe | OGT
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer - Aguado - 2021 - Molecular Oncology - Wiley Online Library
Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer | SpringerLink
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
BioModels
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer - Aguado - 2021 - Molecular Oncology - Wiley Online Library
Cancers | Free Full-Text | Targeting MET Amplification as a New Oncogenic Driver
